NCT01290939View on ClinicalTrials.gov

Bevacizumab and Lomustine for Recurrent GBM

PHASE3CompletedINTERVENTIONAL
Enrollment

592

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

October 31, 2015

Study Completion Date

April 30, 2020

Conditions
Glioblastoma MultiformeCognition DisordersDisability Evaluation
Interventions
BIOLOGICAL

bevacizumab

DRUG

lomustine

GENETIC

DNA methylation analysis

OTHER

laboratory biomarker analysis

PROCEDURE

cognitive assessment

PROCEDURE

quality-of-life assessment

Trial Locations (2)

Unknown

Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam

Medisch Centrum Haaglanden - Westeinde, The Hague

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT01290939 - Bevacizumab and Lomustine for Recurrent GBM | Biotech Hunter | Biotech Hunter